Ann: Agreement for anticipated Aspiral China sales approx USD45M, page-212

Hi

It all makes perfect sense that iTest were quick to recognise the potential of MABR and have shown in their actions to date that they are going to use it to drive their growth exponentially.

That was my first thought when the initial iTEST agreement was announced. The significance of the 'exclusivity' built into the agreement was not lost with me, as it signaled the intention of iTEST in the coming years and how they saw MABR as a competitive advantage among its peers.

I have no doubt where that partnership is heading and how Fluence China will work with iTEST to further expand on the initial agreement.

If there is however an influx of orders in the near future, Fluence will need to raise some capital to meet that demand.